AR066311A1 - Moleculas de anticuerpos anti proteina hsp90 fungica y acidos nucleicos que los codifican - Google Patents
Moleculas de anticuerpos anti proteina hsp90 fungica y acidos nucleicos que los codificanInfo
- Publication number
- AR066311A1 AR066311A1 ARP080101768A ARP080101768A AR066311A1 AR 066311 A1 AR066311 A1 AR 066311A1 AR P080101768 A ARP080101768 A AR P080101768A AR P080101768 A ARP080101768 A AR P080101768A AR 066311 A1 AR066311 A1 AR 066311A1
- Authority
- AR
- Argentina
- Prior art keywords
- fungica
- hsp90
- nucleic acids
- protein antibodies
- acids coding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Péptido scFv, el cual comprende un dominio VH y un dominio VL enlazados por un espaciador de aminoácidos. El dominio VH comprende una secuencia con una identidad de secuencia de cuando menos el 80% con la secuencia de la SEQ ID N°:64. El dominio VL comprende una secuencia con una identidad de secuencia de cuando menos el 80% con la secuencia de la SEQ ID N°:66. El péptido scFv también comprende la sustitucion o la supresion de un aminoácido en el dominio VH en la posicion correspondiente a C28. También composiciones farmacéuticas que comprenden tales péptidos así como el uso de las mismas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07107140 | 2007-04-27 | ||
| EP07113353 | 2007-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066311A1 true AR066311A1 (es) | 2009-08-12 |
Family
ID=39717534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101768A AR066311A1 (es) | 2007-04-27 | 2008-04-25 | Moleculas de anticuerpos anti proteina hsp90 fungica y acidos nucleicos que los codifican |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20100113355A1 (es) |
| EP (2) | EP2144932A1 (es) |
| JP (1) | JP2010524485A (es) |
| KR (1) | KR20100017387A (es) |
| CN (1) | CN101679517A (es) |
| AR (1) | AR066311A1 (es) |
| AU (1) | AU2008244308A1 (es) |
| BR (1) | BRPI0810827A2 (es) |
| CA (1) | CA2685136A1 (es) |
| CL (1) | CL2008001202A1 (es) |
| CR (1) | CR11059A (es) |
| EA (1) | EA200901441A1 (es) |
| EC (1) | ECSP099765A (es) |
| GT (1) | GT200900276A (es) |
| IL (1) | IL201445A0 (es) |
| MA (1) | MA31384B1 (es) |
| MX (1) | MX2009011595A (es) |
| PE (1) | PE20090728A1 (es) |
| TN (1) | TN2009000442A1 (es) |
| TW (1) | TW200902714A (es) |
| WO (2) | WO2008132134A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100113355A1 (en) | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| WO2016014839A2 (en) * | 2014-07-23 | 2016-01-28 | Ohio State Innovation Foundation | Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72) |
| CN105652011B (zh) * | 2014-11-20 | 2017-09-22 | 深圳市安群生物工程有限公司 | 检测人HSP90α‑2蛋白的荧光免疫层析试纸及其制备方法 |
| CN113845591B (zh) * | 2018-10-30 | 2023-10-31 | 迈威(上海)生物科技股份有限公司 | Hsp90抗体及其在抗真菌感染中的应用 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US20240398982A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732852A (en) * | 1981-11-20 | 1988-03-22 | Cetus Corporation | Site directed peptidase cleavage |
| US4670382A (en) | 1983-12-02 | 1987-06-02 | Temple University--of the Commonwealth System of Higher Education | Monoclonal antibody to Candida albicans cytoplasmic antigens and methods of preparing same |
| US4806465A (en) * | 1984-01-16 | 1989-02-21 | Temple University Of The Commonwealth System Of Higher Education | Cytoplasmic antigens of candida albicans and methods of using the same |
| GB8506373D0 (en) | 1985-03-12 | 1985-04-11 | Axon Healthcare Ltd | Antigens antibodies |
| GB8915019D0 (en) * | 1989-06-30 | 1989-08-23 | Matthews Ruth C | Medicaments |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| GB2270076A (en) | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
| AU769235B2 (en) | 1999-04-09 | 2004-01-22 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| ES2287044T3 (es) | 2000-01-25 | 2007-12-16 | Oklahoma Medical Research Foundation | Procedimiento universal para el replegamiento de proteinas recombinantes. |
| GB0008305D0 (en) * | 2000-04-06 | 2000-05-24 | Neutec Pharma Plc | Treatment of fungal infections |
| AU2001272001A1 (en) | 2000-07-14 | 2002-01-30 | Healthcite, Inc. | Method and system for providing medical information |
| EP1423080A4 (en) * | 2001-03-01 | 2009-06-03 | Conforma Therapeutics Corp | PROCESS FOR TREATING PROLIFERATIVE GENETIC DISORDERS WITH HSP90 INHIBITORS |
| GB0127983D0 (en) | 2001-11-22 | 2002-01-16 | Neutec Pharma Plc | Treatment of micro-organism infection |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| GB0409077D0 (en) * | 2004-04-23 | 2004-05-26 | Neutec Pharma Plc | Treatment of fungal infections |
| US20080038267A1 (en) * | 2004-07-02 | 2008-02-14 | Neutec Pharma Limited | Treatment Of Cancer |
| US20100113355A1 (en) | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| WO2008132174A1 (en) | 2007-04-27 | 2008-11-06 | Novartis Ag | An immunoglobulin composition |
-
2006
- 2006-04-24 US US12/597,229 patent/US20100113355A1/en not_active Abandoned
-
2008
- 2008-04-24 EP EP08736541A patent/EP2144932A1/en not_active Withdrawn
- 2008-04-24 JP JP2010504689A patent/JP2010524485A/ja active Pending
- 2008-04-24 CA CA002685136A patent/CA2685136A1/en not_active Abandoned
- 2008-04-24 EA EA200901441A patent/EA200901441A1/ru unknown
- 2008-04-24 BR BRPI0810827-7A2A patent/BRPI0810827A2/pt not_active Application Discontinuation
- 2008-04-24 EP EP08749716A patent/EP2152746A1/en not_active Withdrawn
- 2008-04-24 MX MX2009011595A patent/MX2009011595A/es unknown
- 2008-04-24 KR KR1020097024646A patent/KR20100017387A/ko not_active Application Discontinuation
- 2008-04-24 US US12/150,076 patent/US7722869B2/en not_active Expired - Fee Related
- 2008-04-24 AU AU2008244308A patent/AU2008244308A1/en not_active Abandoned
- 2008-04-24 CN CN200880013913A patent/CN101679517A/zh active Pending
- 2008-04-24 WO PCT/EP2008/055006 patent/WO2008132134A1/en active Application Filing
- 2008-04-24 WO PCT/EP2008/055037 patent/WO2008132152A1/en active Application Filing
- 2008-04-25 PE PE2008000709A patent/PE20090728A1/es not_active Application Discontinuation
- 2008-04-25 CL CL2008001202A patent/CL2008001202A1/es unknown
- 2008-04-25 TW TW097115380A patent/TW200902714A/zh unknown
- 2008-04-25 AR ARP080101768A patent/AR066311A1/es unknown
-
2009
- 2009-10-09 CR CR11059A patent/CR11059A/es not_active Application Discontinuation
- 2009-10-11 IL IL201445A patent/IL201445A0/en unknown
- 2009-10-23 GT GT200900276A patent/GT200900276A/es unknown
- 2009-10-23 TN TNP2009000442A patent/TN2009000442A1/fr unknown
- 2009-11-20 MA MA32355A patent/MA31384B1/fr unknown
- 2009-11-27 EC EC2009009765A patent/ECSP099765A/es unknown
-
2010
- 2010-03-08 US US12/719,049 patent/US20100166758A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010524485A (ja) | 2010-07-22 |
| KR20100017387A (ko) | 2010-02-16 |
| CA2685136A1 (en) | 2008-11-06 |
| MA31384B1 (fr) | 2010-05-03 |
| ECSP099765A (es) | 2009-12-28 |
| EP2144932A1 (en) | 2010-01-20 |
| US20090136484A1 (en) | 2009-05-28 |
| MX2009011595A (es) | 2009-12-08 |
| CN101679517A (zh) | 2010-03-24 |
| TN2009000442A1 (en) | 2011-03-31 |
| IL201445A0 (en) | 2010-06-16 |
| US20100113355A1 (en) | 2010-05-06 |
| EA200901441A1 (ru) | 2010-04-30 |
| US7722869B2 (en) | 2010-05-25 |
| GT200900276A (es) | 2010-05-21 |
| CL2008001202A1 (es) | 2008-12-19 |
| WO2008132134A9 (en) | 2009-07-09 |
| PE20090728A1 (es) | 2009-07-02 |
| TW200902714A (en) | 2009-01-16 |
| US20100166758A1 (en) | 2010-07-01 |
| WO2008132152A1 (en) | 2008-11-06 |
| AU2008244308A1 (en) | 2008-11-06 |
| BRPI0810827A2 (pt) | 2014-10-29 |
| EP2152746A1 (en) | 2010-02-17 |
| WO2008132134A1 (en) | 2008-11-06 |
| CR11059A (es) | 2009-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120532A1 (es) | ANTICUERPOS ANTI-ActRIIB | |
| UY31123A1 (es) | Proteinas de fusion natriureticas | |
| ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
| EP3670536A3 (en) | Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| AR071874A1 (es) | Proteinas de dominio de armazon basadas en fibronectina multivalentes | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| MX2015000397A (es) | Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos. | |
| EA201491049A1 (ru) | Противораковый слитый белок | |
| BR112014006390A2 (pt) | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano | |
| NO20063026L (no) | Antistoffer | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| PE20120170A1 (es) | Variantes de union a anti-albumina de suero mejoradas | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| CL2012002095A1 (es) | Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa | |
| EA201391756A1 (ru) | Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами | |
| BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
| MX356517B (es) | Polipéptidos de fusión de serpina y métodos de uso de los mismos. | |
| AR066311A1 (es) | Moleculas de anticuerpos anti proteina hsp90 fungica y acidos nucleicos que los codifican | |
| UA118167C2 (uk) | Пептид та його застосування | |
| WO2010142551A8 (en) | Amino acid sequences directed against receptors to cytokines belonging to the il-17 family | |
| UA115436C2 (uk) | Протираковий злитий протеїн | |
| AR109450A1 (es) | Moléculas de unión a ilt7 y métodos de uso de las mismas | |
| WO2008093058A3 (en) | Peptides and their use | |
| WO2012091564A3 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |